Brief: Vir Biotechnology Awarded Barda Funding To Support Development Of Antibody Platform Technologies For Global Infectious Disease Threats
03/10/2023 13:21
Oct 3 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY AWARDED BARDA FUNDING TO SUPPORT
DEVELOPMENT
OF ANTIBODY PLATFORM TECHNOLOGIES FOR GLOBAL INFECTIOUS DISEASE
THREATS
* VIR BIOTECHNOLOGY - INVESTMENT OF ABOUT $50 MILLION FROM
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY INCLUDES
$40 MILLION IN PROJECT NEXTGEN FUNDS
Source text for Eikon: ID:nGNX72xdCS
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO